BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma

Chengzhang Shi, Zhao Ye, Jie Han, Xiaoqing Ye, Wenchao Lu, Chenxing Ji, Zizhou Li, Zengyi Ma, Qilin Zhang, Yichao Zhang, Wenqiang He, Zhengyuan Chen, Xiaoyun Cao, Xuefei Shou, Xiang Zhou, Yongfei Wang, Zhaoyun Zhang, Yiming Li, Hongying Ye, Min He, Hong Chen, Haixia Cheng, Jun Sun, Jianyong Cai, Chuanxin Huang, Fei Ye, Cheng Luo, Bing Zhou, Hong Ding, Yao ZhaoNeuro-Oncology 2020 · DOI

Abstract

In this study, we determined the overexpression of BRD4 in NFPA and GHPA and assessed the effects of BRD4 inhibitors on PA cells in vitro and in vivo. Our findings suggest that BRD4 is a promising therapeutic target for NFPA and GHPA.
BibTeX
@inproceedings{shi2020brd,
  author = {Chengzhang Shi and Zhao Ye and Jie Han and Xiaoqing Ye and Wenchao Lu and Chenxing Ji and Zizhou Li and Zengyi Ma and Qilin Zhang and Yichao Zhang and Wenqiang He and Zhengyuan Chen and Xiaoyun Cao and Xuefei Shou and Xiang Zhou and Yongfei Wang and Zhaoyun Zhang and Yiming Li and Hongying Ye and Min He and Hong Chen and Haixia Cheng and Jun Sun and Jianyong Cai and Chuanxin Huang and Fei Ye and Cheng Luo and Bing Zhou and Hong Ding and Yao Zhao},
  title = {{BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma}},
  booktitle = {Neuro-Oncology},
  year = {2020},
  doi = {10.1093/neuonc/noaa084},
}

Loading related content...

Figure